Page 9 - Sci Communications News Today

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Penumbra, Inc.

Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference Nachrichtenquelle: globenewswire  |  13.01.2021, 00:21  |  131   |  0  IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care con...

Share this article HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress from its ongoing license agreement with AstraZeneca (LSE: AZN) (STO: AZN) (NASDAQ: AZN) under which the program has achieved a preclinical milestone. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bispecific and multi-specif...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the ... ZIOPHARM Oncology IncDecember 21, 2020 GMT – Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transf...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic ... Athenex, Inc.December 15, 2020 GMT Klisyri is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launc...

Share: DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. "The submission of our NDA represents a significant milestone for the Company. We look forward to working with the FDA duri...

is the first FDA approved proprietary product for Athenex First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall will launch Klisyri in the U.S. in first quarter 2021 BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of no...

Share: BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the companys clinical development programs. "We are very pleased to welcome Diego to our team," said Paula Ragan, Ph.D....